Tensions Rise Over Proposed Drug Testing for Welfare Recipients
WITH ice addiction declared a public health crisis, the Government’s proposed drug-testing trial of welfare recipients couldn’t come at a better time.
Methamphetamine-related deaths have doubled in Australia in just six years, according to new findings by the National Drug and Alcohol Research Centre.
Back in May, Prime Minister Malcolm Turnbull defended the controversial trial by saying: “If you love somebody who is addicted to drugs, don’t you want to get them off drugs?”
Naturally, but the fact is that addicts won’t seek treatment or be motivated to change unless they see a reason to do so.
THE DRUG ADVISORY COUNCIL OF AUSTRALIA SUPPORTS- More drug rehabilitation that enables illicit drug users to move toward drug free lifestyles – Court ordered and supervised detoxification & rehabilitation - Less illicit drug users, drug pushers and drug related crimes
A Colorado district attorney drew attention this week after he pronounced marijuana to be a "gateway drug to homicide."
The controversial remarks made by 4th Judicial District Attorney Dan May came at a news conference Tuesday about a large black market marijuana bust in the state, KKTV reported. Thirteen people have been indicted, Colorado Attorney General Cynthia Coffman announced.
Black market marijuana bust leaves bruises on Colorado's marijuana industry July 2017
Cannabis is the most widely used illicit drug in the United States, and trends show increasing use in the general population. As cannabis consumption rises, there has been significant emerging evidence for cannabis-related risks to health.1
Numerous lines of evidence suggest a correlation between cannabis consumption and a variety of psychiatric conditions, including cannabis-induced psychosis (CIP). While it can be difficult to differentiate CIP from other psychoses, CIP holds distinguishing characteristics, which may aid in its diagnosis. Given the increasing push toward cannabis legalization, assessing CIP and employing timely treatments is critical.
Specifically in youth, there is a direct relationship between cannabis use and its risks. The lack of knowledge surrounding its detrimental effects, combined with misunderstandings related to its therapeutic effects, has potential for catastrophic results
Published July 2017 By Honor Whiteman
Researchers say that adolescents who increase their use of the drug may be more susceptible to psychotic-like episodes.
Studies have long suggested a link between marijuana use and psychosis. New research sheds further light on this association, after finding that teenagers who increase their use of the drug are more likely to experience psychotic-like episodes…Compared with teenagers in the general population, the researchers found that teenagers who increased their frequency of marijuana use from occasionally to weekly or daily were at 159 percent greater risk of having recurrent PLEs.
(Cannabis use and psychotic-like experiences trajectories during early adolescence: the coevolution and potential mediators http://onlinelibrary.wiley.com/doi/10.1111/jcpp.12765/full )
Published: 10 July 2017
In The Lancet Psychiatry, Schoeler and colleagues present a study describing the mediating effect of medication adherence on the association between continued cannabis use and relapse risk in patients with first-episode psychosis. They have previously reported a relapse rate of 36% in this patient group over a 2-year period.
Acknowledging the potential risk of psychosis relapse related to the high proportion of patients continuing cannabis use after the onset of psychosis, the current study1 investigates the same patient group consisting of 245 patients, obtaining retrospective data on active cannabis use and medication adherence shortly after illness onset, as well as risk of relapse at 2-year follow-up. The authors find that relapse of psychosis associated with continued cannabis use is partly mediated through non-adherence to prescribed antipsychotic medication.
It is well established that cannabis use increases the risk of schizophrenia, not only from the early Swedish conscript studies but also from studies on people who use sinsemilla in London, UK, showing that high potency cannabis increases the risk of schizophrenia. Twin studies from Norway have shown that cannabis increases the risk of psychosis, even when controlling for genetic factors. There has been discussion on the direction of the association, as none of these studies can rule out reverse causality, but it seems reasonable to conclude that cannabis is one of many stressors that can precipitate schizophrenia, at least in susceptible individuals.
Taking Action - Stopping Ice
United Nations Office of Drugs & Crime: Drug Prevention & Treatment
Medicinal Cannabis –
Access to medicinal Cannabis Products (TGA)
Access to medicinal cannabis products: steps to using access ...
Presentations, Statements & Conference Resources from WFAD 2018 Forum